|
Jul 1
|
A Promising Depression Drug Works. Psychedelics Are Back.
|
|
Jul 1
|
atai and Beckley Psytech’s psychedelic wins in Phase IIb depression trial
|
|
Jul 1
|
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
|
|
Jul 1
|
Atai and Beckley, set to merge, reveal study success for psychedelic drug
|
|
Jul 1
|
atai Life Sciences Announces $50 Million Private Placement Financing
|
|
Jul 1
|
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
|
|
Jun 25
|
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
|
|
Jun 19
|
Trump Trade: President said to weigh possible U.S. strike against Iran
|
|
Jun 19
|
Psychedelic advocates hopeful Trump administration will support space, STAT says
|
|
Jun 19
|
This Illegal Psychedelic Is Hailed as a ‘Revolutionary Breakthrough’
|
|
May 21
|
Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies
|
|
May 21
|
Home Depot backs outlook as U.S. sales ticked up: Morning Buzz
|
|
May 20
|
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
|
|
May 14
|
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
|
|
May 13
|
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
|
|
Apr 11
|
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
|
|
Mar 14
|
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
|
|
Mar 11
|
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
|
|
Feb 20
|
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
|
|
Dec 30
|
US Penny Stocks To Consider In December 2024
|